SCHEMBL10240110

SCHEMBL10240110

[C-]#[N+]c1ccc(OC)c(C(=O)Nc2c[nH]nc2-c2nc3cc(CN4CCOCC4)ccc3[nH]2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.41
AURKB Q96GD4 6/20 0.41
CDK1 P06493 5/20 0.41
CCNB1 P14635 5/20 0.41
CDK2 P24941 4/20 0.41
PDPK1 O15530 1/20 0.40
ABCB1 P08183 1/20 0.40
MAPT P10636 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
FGFR1 P11362 3/20 0.39
FGFR2 P21802 3/20 0.39
FGFR3 P22607 3/20 0.39
CHEK1 O14757 2/20 0.39
CDK7 P50613 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12252946 0.91 AURKA (0.44) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL12303277 0.90 AURKA (0.43) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL12772132 0.89 AURKA (0.43) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL8305800 0.89 LMNA (0.49) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL12252754 0.88 AURKA (0.48) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL8302923 0.88 AURKA (0.43) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL8299904 0.88 AURKA (0.42) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL12582585 0.88 AURKA (0.45) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL14780744 0.87 AURKA (0.43) AURKAAURKBCDK1CCNB1CDK2
SCHEMBL546083 0.87 ITK (0.44) AURKAAURKBCDK1CCNB1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778936-B2 Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases ASTEX THERAPEUTICS LIMITED (GB) 2014-07-15 US disclosed
US-8399442-B2 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED (GB) 2013-03-19 US disclosed
US-20120190673-A1 PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-07-26 US disclosed
US-8110573-B2 Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents ASTEX THERAPEUTICS LIMITED (GB) 2012-02-07 US disclosed
US-20100004232-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (UK) 2010-01-07 US disclosed
US-20080132495-A1 Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases ASTEX THERAPEUTICS LIMITED (GB) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004232-A1 Pharmaceutical Compounds ERBB3, ABL1, RET AURKA 98/4885AURKB 67/4885CDK1 316/4885
US-20120190673-A1 PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES CDK3, CDK1, AURKA AURKA 3/4885AURKB 9/4885CDK1 2/4885
US-20080132495-A1 Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases CDK3, CDK1, AURKA AURKA 3/4885AURKB 9/4885CDK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.